

Benelux Precision Medicine Forum

12-13 June 2018, Utrecht, The Netherlands



@precisionforum #beneluxpmf

Programme

Sponsors:

BLUEBEE

FOUNDATION
MEDICINE®



Janssen
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

Janssen
Diagnostics

Exhibitors:

OncoDNA
THE CANCER THERANOSTIC COMPANY

Covaris®

HTG Molecular

KYVOR
GENOMICS

eurofins
Clinical Diagnostics

Partners:

Vereniging
Innovatieve
Geneesmiddelen

inspire
2live

UTRECHT
LIFE SCIENCES

ESPT
European Society of Pharmacogenomics and Personalized Therapy
A Multiple Society for Individualized Medicine

flanders.bio

www.precisionmedicineforum.com

Programme

Benelux Precision Medicine Forum is preceded by the free to attend Permides 2018 conference – Empowering Personalized Medicine through Digital Solutions. (9.00-12.30) For more information visit www.precisionmedicineforum.com/benelux-2018

12 June 2018

12.20 Registration and Networking Lunch

13.30 Opening Remarks

13.35 Improving the Delivery of Value-Based Personalized Cancer Care: Health Economics of Liquid Biopsies for Treatment Targeting and Monitoring



Maarten J. IJzerman, PhD, Professor and Chair of Cancer Health Services Research University of Melbourne and Victorian Comprehensive Cancer Center, Melbourne, Australia
Professor of Health Technology and Services Research, University of Twente

13.55 The economics of precision medicine: establishing value and paying for value

The talk will provide an overview of the issue of establishing whether precision medicines offer value for money, and particularly how value can be measured. Paula will discuss how value is currently measured and introduce new elements of value. She will then present some of the issues on paying for value, particularly in the face of uncertain evidence of effect and also the issues around reimbursement of the test vis-à-vis the treatment.



Paula Lorgelly, Deputy Director, Office of Health Economics, Visiting Professor, Division of Cancer Studies, King's College London

14.15 Healthcare Economics Q&A

14.25 Every Patient Counts - Making Precision Medicine a Reality for European Cancer Patients



Ian Walker, Roche Foundation Medicine

14.45 National scale tumor whole genome sequencing for personalized cancer treatment in the Netherlands



Prof. dr. Edwin Cuppen, Hartwig Medical Foundation, Amsterdam, The Netherlands

15.05 Bridging the innovation gap in biomarker research

Our understanding of disease mechanisms has dramatically increased over the last decades. Molecules involved in disease processes in theory can serve as precise reporters of patient's disease status, and then are referred to as biomarkers. Yet, the speed with which biomarkers are being developed and implemented in patient care tremendously lags behind the speed at which mechanisms of disease are unraveled. This innovation gap to a large extent is caused by suboptimal logistics and infrastructure for clinical validation. Fragmentation of resources, initiatives, collections, regulations etc. is a major cause of the problem, and is due to social, cultural and organizational reasons, rather than technical. Large scale concerted actions are needed to overcome this hurdle, of which the Dutch national infrastructure for personalized medicine and health research Health-RI is a prominent example.



Gerrit A. Meijer, MD, PhD, Head, Dept. of Pathology, Netherlands Cancer Institute; Professor of Oncologic Pathology, University Medical Center Utrecht; BBMRI-NL, EATRIS-NL, Health-RI

15.25 Panel Discussion: Precision Oncology Participants:

Ian Walker, Foundation Medicine

Prof. dr. Edwin Cuppen, Hartwig Medical Foundation, Amsterdam, The Netherlands

Gerrit A. Meijer, MD, PhD, Head, Dept. of Pathology, Netherlands Cancer Institute

15.40 Networking coffee break

16.10 How biomarker validation platforms can complement Precision Medicine to maximize efficiency



Dr. Catherine Larue, CEO Integrate Biobank of Luxembourg (IBBL)

16.35 The current trend for Diagnostics and PM in the Era of Big Data:

- Overview of the leading Diagnostic technologies to drive PM
- Current trend of big data and AI for PM, the opportunities and the challenges



Yiu-Lian Fong, Ph.D, MBA Global Head Diagnostic Innovation, Research and Early Development, and Lab Operations, Johnson and Johnson Innovation

17.00 Diagnostics as a key to unlock Precision Medicine



Bregje van Oorschot PhD, Diagnostics Manager Oncology, AstraZeneca

17.20 Panel Discussion: Participants:

Catherine Larue
Yiu Lian Fong
Bregje van Oorschot

17.45 Networking Drinks Reception

13 June 2018

9.10-9.40 Clinical and Translational Sciences: 'Personalised Medicine in Europe'



Jean-Luc Sanne, Senior Policy Officer Unit for the Innovative and Personalised Medicine Unit, Health Research Directorate in DG Research and Innovation

9.40 Quantifying the benefits of personalised medicines to patients, society and healthcare systems

Charles River Associates has conducted an evidence-based analysis on behalf of The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Biopharmaceutical Enterprises (EBE), to characterise and quantify the benefits of personalised medicines to patients, society and healthcare systems.

This study seeks to identify barriers and enablers to the development and adoption of PM in Europe and elaborate strategic recommendations for decision-makers to overcome these barriers and incentivise the development and adoption of PM in Europe.



Anthony Barron, Associate Principal in the Life Sciences Practice, Charles River Associates

10.00 Innovations in Molecular Insights in Personalized Health and Medicine

We have reached a fantastic period in science. Exponential developments in molecular technologies including next gene sequencing and mass spectrometry have enabled us to obtain increasing insights in the molecular components of human biology and their interactions. Novel personalized diagnostics and of high precision medicines that interfere with selected disease mechanisms are now driving the new paradigm of precision medicine. Even extending our ambitions towards personalized health, we now aim to translate interdisciplinary molecular research to knowledge, understanding and actionable decisions for people to maintain and/or improve their health. We are, however, rediscovering that human physiology is a highly complex system and that we need multiple viewing angles to begin to understand the complexity and identify its key nodes. Integration of various 'omics analysis platforms is a powerful approach towards that end.



Alain van Gool, Professor Personalized Healthcare, Radboud University Medical Center, DTL, EATRIS, Health-RI

10.20 Q&A

10.30 Networking Coffee Break

11.00 A Systems Medicine approach to understand, re-classify and treat chronic inflammatory diseases in a personalized way



Timothy Radstake MD, PhD, Professor of Translational Immunology within the departments of Rheumatology & Clinical Immunology and on the Laboratory of Translational Immunology, UMC Utrecht

11.20 Precision Medicine in respiratory disease



Prof. Dr. A.H. (Anke-Hilse) Maitland-van der Zee, Professor Precision Medicine in Respiratory Disease Academisch Medisch Centrum (AMC)

Programme

11.40 Translational Systemics for Precision Medicine



Prof. Dr. Kristel Van Steen, GIGA-R University of Liege, KU Leuven, Belgium

12.00 Precision Medicine – A data Enabled Reality



Michelle Garred, Director of Marketing, Bluebee

12.20 Networking Lunch

13.20 Roundtable sessions

14.30 Your DNA as a guide for Personal Drug Therapy: it is here today!



Prof. Dr. Ron van Schaik, International Expert Center Pharmacogenetics Dept. Clinical Chemistry Erasmus University Medical Center

14.50 Biobanks as vehicles for researching population health

How we can use detailed omics and other information from individuals in the general population to improve prevention and prediction of (chronic) disease. At the same time we can learn about disease mechanisms, the natural history of disease. Furthermore we have to think about feedback of information to participants so they can act on that.



Cisca Wijmenga, Professor of Human Genetics, University of Groningen and University Medical Center Groningen

15.10 Networking Coffee

15.30 Personalized Medicine - but this time for real!



Dr. h.c. Peter Kapitein, Patient Advocate Inspire2Live

15.50 A family physician's vision of precision medicine in daily practice: implementing genetics effectively

A (pharmaco) genetics case in daily primary care practice
Genetic educational needs, PhD results
Genetics is team work
Genetics, Ehealth and applications in daily practice
Genetics education: don't go too fast or implementation won't take place!



Dr. E.J.F. Houwink, Assistant Prof LUMC, General Practitioner-General Genetics in primary care

16.10 Panel Discussion: The Clinical Implementation of Precision Medicine:

Dr. E.J.F. Houwink, Assistant Prof LUMC, General Practitioner-General Genetics in primary care

Dr. h.c. Peter Kapitein, Patient Advocate Inspire2Live

Prof. Dr. Ron van Schaik, International Expert Center Pharmacogenetics Dept. Clinical Chemistry Erasmus University Medical Center

Cisca Wijmenga, Professor of Human Genetics, University of Groningen and University Medical Center Groningen

16.30 Conference Close

REGISTER NOW!

www.precisionmedicineforum.com/benelux-2018/register